TrialThe Lancet. Oncology2014

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Susan O'Brien et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.